[go: up one dir, main page]

PE20221048A1 - Lactamas biciclicas como inhibidores de rip1 cinasa - Google Patents

Lactamas biciclicas como inhibidores de rip1 cinasa

Info

Publication number
PE20221048A1
PE20221048A1 PE2022000233A PE2022000233A PE20221048A1 PE 20221048 A1 PE20221048 A1 PE 20221048A1 PE 2022000233 A PE2022000233 A PE 2022000233A PE 2022000233 A PE2022000233 A PE 2022000233A PE 20221048 A1 PE20221048 A1 PE 20221048A1
Authority
PE
Peru
Prior art keywords
methyl
ring
kinase inhibitors
bicyclic lactams
rip1 kinase
Prior art date
Application number
PE2022000233A
Other languages
English (en)
Inventor
Gregory Hamilton
Craig Stivala
Huifen Chen
Guiling Zhao
Snahel Patel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20221048A1 publication Critical patent/PE20221048A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE LACTAMAS BICICLICAS DE FORMULA (I) EN DONDE R1, X, Z1, L, n, EL ANILLO A, EL ANILLO B Y EL ANILLO C SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: N-((S)-5-METIL-4-OXO-2,3,4,5-TETRAHIDROBENZO[B][1.4]OXAZEPIN-3-IL)-6-(TRIFLUOROMETIL)-5,6,7,8-TETRAHIDROIMIDAZO[1,5-A]PIRIDIN-3-CARBOXAMIDA; 5-METIL-N-((S)-5-METIL-4-OXO-2,3,4,5-TETRAHIDROBENZO[B][1.4]OXAZEPIN-3-IL)-4,5,6,7-TETRAHIDRO-2H-INDAZOL-3-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUE INTERACTUA CON EL RECEPTOR 1 (RIP1) CINASA SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL INTESTINO IRRITABLE, ENFERMEDAD DE CROHN, COLITIS ULCEROSA.
PE2022000233A 2015-07-02 2016-07-01 Lactamas biciclicas como inhibidores de rip1 cinasa PE20221048A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188153P 2015-07-02 2015-07-02
US201562387295P 2015-12-23 2015-12-23
PCT/US2016/040659 WO2017004500A1 (en) 2015-07-02 2016-07-01 Bicyclic lactams and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20221048A1 true PE20221048A1 (es) 2022-06-30

Family

ID=56411952

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002860A PE20180501A1 (es) 2015-07-02 2016-07-01 Lactamas biciclicas y metodos de uso de las mismas
PE2022000233A PE20221048A1 (es) 2015-07-02 2016-07-01 Lactamas biciclicas como inhibidores de rip1 cinasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2017002860A PE20180501A1 (es) 2015-07-02 2016-07-01 Lactamas biciclicas y metodos de uso de las mismas

Country Status (24)

Country Link
US (2) US10988459B2 (es)
EP (2) EP3317269B1 (es)
JP (2) JP6785252B2 (es)
KR (2) KR102104911B1 (es)
CN (3) CN112979660A (es)
AU (4) AU2016287581B2 (es)
CA (2) CA3094197C (es)
CL (2) CL2017003486A1 (es)
CO (1) CO2017013709A2 (es)
CR (1) CR20170573A (es)
ES (1) ES2930749T3 (es)
IL (2) IL255830B (es)
MA (2) MA42302A (es)
MX (2) MX380753B (es)
MY (1) MY192762A (es)
PE (2) PE20180501A1 (es)
PH (1) PH12018500034A1 (es)
PL (1) PL3317269T3 (es)
RU (1) RU2716136C2 (es)
SG (1) SG10201913880XA (es)
TW (2) TWI788830B (es)
UA (1) UA122150C2 (es)
WO (1) WO2017004500A1 (es)
ZA (1) ZA201707812B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913880XA (en) 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
US10787462B2 (en) 2015-10-23 2020-09-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017109724A1 (en) * 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
TWI781920B (zh) * 2016-02-05 2022-11-01 美商戴納立製藥公司 化合物、組合物及方法
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP2020509009A (ja) 2017-02-27 2020-03-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としての複素環式アミド
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200737B (zh) * 2017-06-29 2019-03-26 武汉药明康德新药开发有限公司 叔丁氧羰基-3-(羟甲基)-[1,2,3]三氮唑[1,5-a]哌啶-6-酰胺制法
KR102664604B1 (ko) 2017-07-14 2024-05-14 에프. 호프만-라 로슈 아게 이환형 케톤 화합물 및 이의 사용 방법
EP3694858B1 (en) 2017-10-11 2023-01-11 F. Hoffmann-La Roche AG Bicyclic compounds for use as rip1 kinase inhibitors
AU2018360270A1 (en) 2017-10-31 2020-03-26 F. Hoffmann-La Roche Ag Bicyclic sulfones and sulfoxides and methods of use thereof
JP7398391B2 (ja) * 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
JP2021523226A (ja) 2018-05-03 2021-09-02 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
US10975064B2 (en) * 2018-05-03 2021-04-13 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
EP3816163A4 (en) * 2018-06-26 2022-04-13 Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences CELL NECROSIS INHIBITORS, METHOD OF MANUFACTURE THEREOF AND USE THEREOF
CN110642874B (zh) * 2018-06-26 2023-03-28 中国科学院上海有机化学研究所 一类细胞坏死抑制剂及其制备方法和用途
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
WO2020054657A1 (ja) * 2018-09-10 2020-03-19 科研製薬株式会社 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬
CN109134448B (zh) * 2018-10-16 2020-11-27 中南大学湘雅医院 杂环化合物及其盐、制备方法、用途和药物
CN113302193A (zh) * 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
TWI724753B (zh) * 2019-01-25 2021-04-11 大陸商北京賽特明強醫藥科技有限公司 醯胺基橋連雜環類化合物、及其組合物與應用
AR118243A1 (es) 2019-03-07 2021-09-22 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
AU2020285269B2 (en) * 2019-05-31 2022-11-17 Medshine Discovery Inc. Bicyclic compound as RIP-1 kinase inhibitor and application thereof
CN110183442A (zh) * 2019-06-06 2019-08-30 无锡合全药业有限公司 一种1 -(乙氧羰基)咪唑并[1, 5]吡啶-6-羧酸的合成方法
BR112022002580A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
WO2021043966A1 (en) * 2019-09-06 2021-03-11 Inflazome Limited Nlrp3 inhibitors
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
PH12022550537A1 (en) 2019-09-06 2023-03-20 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same.
IL291665B2 (en) 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
FI4055021T3 (fi) 2019-11-07 2025-12-16 Rigel Pharmaceuticals Inc Heterosyklisiä rip1:tä estäviä yhdisteitä
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
MX2022007518A (es) 2019-12-20 2022-09-19 Pfizer Derivados bencimidazol.
CN115515940A (zh) * 2020-02-28 2022-12-23 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
JP7701162B2 (ja) * 2020-02-28 2025-07-01 科研製薬株式会社 新規ヘテロ芳香族アミド誘導体又はその塩からなる医薬
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
CN116075511B (zh) 2020-04-09 2024-10-29 达萨玛治疗公司 作为sarm1抑制剂的稠合吡唑衍生物
US20230192617A1 (en) 2020-05-19 2023-06-22 Bayer Cropscience Aktiengesellschaft Azabicyclic(thio)amides as fungicidal compounds
US20230234945A1 (en) 2020-06-10 2023-07-27 Bayer Aktiengesellschaft Azabicyclyl-substituted heterocycles as fungicides
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
EP3974414A1 (de) 2020-09-25 2022-03-30 Bayer AG 5-amino substituierte pyrazole und triazole als schädlingsbekämpfungsmittel
WO2022171110A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Fused tricyclic compounds as rip1-kinase inhibitors and uses thereof
WO2022171111A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof
TW202300490A (zh) * 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
JP2024513394A (ja) 2021-04-02 2024-03-25 ジェネンテック， インコーポレイテッド 二環式ケトン化合物を作製するための方法
CN113651810B (zh) * 2021-07-16 2023-10-13 上海毕得医药科技股份有限公司 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法
KR102707109B1 (ko) 2021-08-10 2024-09-20 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
WO2023020486A1 (zh) * 2021-08-17 2023-02-23 广州市恒诺康医药科技有限公司 Rip1激酶抑制剂类化合物及其组合物和用途
US20230060797A1 (en) * 2021-09-02 2023-03-02 Jcr Pharmaceuticals Co., Ltd. Therapeutic compound for neuronal ceroid lipofuscinosis
WO2023119210A1 (ko) 2021-12-24 2023-06-29 제일약품주식회사 Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide
WO2023174374A1 (zh) 2022-03-16 2023-09-21 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
WO2023240379A1 (zh) * 2022-06-13 2023-12-21 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
CN118084889B (zh) * 2024-01-16 2024-09-27 宁夏医科大学 吲哚3-芳基-5-甲酰胺类衍生物及用途
CN119684191A (zh) * 2025-01-22 2025-03-25 中国科学技术大学 一种可见光催化合成β-内酰胺和双环[2,1,1]化合物的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206234A (en) 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
AU7624798A (en) 1996-12-06 1998-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US20030113782A1 (en) 2001-11-26 2003-06-19 Karim Felix D. MAP4Ks as modifiers of branching morphogenesis and methods of use
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2502677A1 (en) 2002-10-23 2004-05-06 Exelixis, Inc. Map2k6 as modifier of branching morphogenensis and methods of use
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
RU2281947C1 (ru) 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
BRPI0620797A2 (pt) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschonkter Haftung anticorpos anti-il-6 que previnem a ligação de il-6 complexado com il-6ralfa a gp130
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
JP2013523766A (ja) * 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
RU2015103119A (ru) 2012-07-13 2016-08-27 Ф. Хоффманн-Ля Рош Аг Антипролиферативные бензо[в]азепин-2-оны
BR112015001830A2 (pt) 2012-08-09 2017-07-04 Hoffmann La Roche composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção
TWI638815B (zh) 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（一）
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2014170892A1 (en) 2013-04-15 2014-10-23 Yeda Research And Development Co. Ltd. Inhibition of rip kinases for treating lysosomal storage diseases
RU2017109122A (ru) * 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
SG10201913880XA (en) 2015-07-02 2020-03-30 Hoffmann La Roche Bicyclic lactams and methods of use thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016287478B2 (en) 2015-07-02 2021-10-21 Janssen Sciences Ireland Uc Antibacterial compounds
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
RU2018126105A (ru) 2015-12-17 2020-01-17 Астекс Терапьютикс Лимитед Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3394072A4 (en) 2015-12-23 2019-05-29 President and Fellows of Harvard College Cortistatin analogs and uses thereof
TWI781920B (zh) * 2016-02-05 2022-11-01 美商戴納立製藥公司 化合物、組合物及方法
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7398391B2 (ja) * 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
BR112022002580A2 (pt) * 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
AR121717A1 (es) * 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
IL255830A (en) 2018-01-31
AU2019203444B2 (en) 2021-01-21
CA3094197C (en) 2023-02-28
ES2930749T3 (es) 2022-12-21
CN107849023A (zh) 2018-03-27
US12281101B2 (en) 2025-04-22
JP6785252B2 (ja) 2020-11-18
BR112018000080A2 (pt) 2018-08-28
NZ737297A (en) 2024-03-22
NZ770222A (en) 2024-05-31
TWI788830B (zh) 2023-01-01
CN112979660A (zh) 2021-06-18
PE20180501A1 (es) 2018-03-09
EP3317269A1 (en) 2018-05-09
CN107849023B (zh) 2021-03-23
JP2021020946A (ja) 2021-02-18
CA3094197A1 (en) 2017-01-05
US20170008877A1 (en) 2017-01-12
AU2016287581A1 (en) 2017-12-07
IL274391B (en) 2022-02-01
AU2016287581B2 (en) 2019-06-06
KR20190143848A (ko) 2019-12-31
RU2018104092A3 (es) 2019-08-05
HK1251899A1 (zh) 2019-04-26
MX380753B (es) 2025-04-01
EP3760625A1 (en) 2021-01-06
KR102603915B1 (ko) 2023-11-21
PL3317269T3 (pl) 2023-01-02
AU2016287581A9 (en) 2018-03-15
US10988459B2 (en) 2021-04-27
CO2017013709A2 (es) 2018-03-28
MY192762A (en) 2022-09-07
JP7190471B2 (ja) 2022-12-15
CR20170573A (es) 2018-02-20
JP2018519319A (ja) 2018-07-19
MA53835A (fr) 2021-08-11
TW202130636A (zh) 2021-08-16
CN111269221B (zh) 2023-09-26
AU2022279425A1 (en) 2023-01-19
MX2017016482A (es) 2018-03-08
CA2988601A1 (en) 2017-01-05
CL2020003007A1 (es) 2021-10-01
ZA201707812B (en) 2024-02-28
AU2019203444A1 (en) 2019-06-06
AU2021202398A1 (en) 2021-05-20
EP3760625B1 (en) 2024-03-27
EP3317269B1 (en) 2022-09-21
CN111269221A (zh) 2020-06-12
KR20180023988A (ko) 2018-03-07
RU2018104092A (ru) 2019-08-05
IL255830B (en) 2021-02-28
WO2017004500A1 (en) 2017-01-05
CL2017003486A1 (es) 2018-08-03
KR102104911B1 (ko) 2020-04-28
TWI763630B (zh) 2022-05-11
WO2017004500A9 (en) 2017-11-30
EP3760625C0 (en) 2024-03-27
SG10201913880XA (en) 2020-03-30
IL274391A (en) 2020-06-30
UA122150C2 (uk) 2020-09-25
MX2021002978A (es) 2021-05-14
TW201716394A (zh) 2017-05-16
MA42302A (fr) 2018-05-09
RU2716136C2 (ru) 2020-03-06
PH12018500034A1 (en) 2018-07-09
US20220348559A1 (en) 2022-11-03
CA2988601C (en) 2021-12-07

Similar Documents

Publication Publication Date Title
PE20221048A1 (es) Lactamas biciclicas como inhibidores de rip1 cinasa
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
MX374346B (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2017010672A (es) Heterociclos biciclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4).
MY150518A (en) Substituted gamma lactams as therapeutic agents
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MA40219B1 (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
MY192029A (en) 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
CY1121649T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglu2
PE20080211A1 (es) Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih
MX2020001979A (es) Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma.
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
EA201692544A1 (ru) 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4(5H)-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ОТРИЦАТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ MGLUR2
EA201891609A1 (ru) Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
BR112015007503A2 (pt) derivados de oxazolina terapeuticamente ativos
EA201891611A1 (ru) Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
JO3601B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2018008449A (es) Tratamiento de eccema de las manos.